DOXY 200 Drug Patent Profile
When do Doxy 200 patents expire, and what generic alternatives are available?
Doxy 200 is a drug marketed by Fresenius Kabi Usa and is included in one NDA.
The generic ingredient in DOXY 200 is doxycycline hyclate. There is one drug master file entry for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxy 200
A generic version of DOXY 200 was approved as doxycycline hyclate by STRIDES PHARMA on March 29th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DOXY 200?
- What are the global sales for DOXY 200?
- What is Average Wholesale Price for DOXY 200?
Summary for DOXY 200
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 52 |
| Patent Applications: | 2,651 |
| DailyMed Link: | DOXY 200 at DailyMed |
Pharmacology for DOXY 200
| Drug Class | Tetracycline-class Drug |
US Patents and Regulatory Information for DOXY 200
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | DOXY 200 | doxycycline hyclate | INJECTABLE;INJECTION | 062475-002 | Dec 9, 1983 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
